We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
First Financial Corp
THFF
$945M
| $573K | ﹤0.01% |
10,576
+8
| +0.1% | +$398 |
|
1302
Impinj
PI
$5.17B
| $571K | ﹤0.01% |
5,142
| – | – |
|
1303
Aurinia Pharmaceuticals
AUPH
$2.18B
| $568K | ﹤0.01% |
67,015
+27
| +0% | +$216 |
|
1304
Phibro Animal Health
PAHC
$1.55B
| $567K | ﹤0.01% |
22,203
-988
| -4% | -$21.5K |
|
1305
Kinder Morgan
KMI
$70.3B
| $565K | ﹤0.01% |
19,217
-557
| -3% | -$15.3K |
|
1306
Alaska Air
ALK
$4.72B
| $561K | ﹤0.01% |
11,332
-322
| -3% | -$15.6K |
|
1307
UFP Industries
UFPI
$4.67B
| $560K | ﹤0.01% |
5,638
-112
| -2% | -$11.3K |
|
1308
Darling Ingredients
DAR
$10B
| $560K | ﹤0.01% |
14,764
-296
| -2% | -$9.74K |
|
1309
Icon
ICLR
$13.1B
| $559K | ﹤0.01% |
3,840
| – | – |
|
1310
Kennametal
KMT
$2.25B
| $557K | ﹤0.01% |
24,281
+4,502
| +23% | +$93.8K |
|
1311
Saia
SAIA
$9.29B
| $555K | ﹤0.01% |
2,026
-120
| -6% | -$34.2K |
|
1312
Camden Property Trust
CPT
$12.3B
| $554K | ﹤0.01% |
4,917
+3,570
| +265% | +$412K |
|
1313
Zebra Technologies
ZBRA
$16.8B
| $549K | ﹤0.01% |
1,782
-90
| -5% | -$24.4K |
|
1314
Midland States Bancorp
MSBI
$683M
| $549K | ﹤0.01% |
31,719
+6,419
| +25% | +$109K |
|
1315
Oshkosh
OSK
$9.49B
| $545K | ﹤0.01% |
4,804
-1,357
| -22% | -$132K |
|
1316
Kaspi.kz JSC
KSPI
$20.3B
| $539K | ﹤0.01% |
6,345
| – | – |
|
|
YMAB
1317
DELISTED
Y-mAbs Therapeutics
YMAB
| $539K | ﹤0.01% |
119,425
-34,028
| -22% | -$153K |
|
1318
BRC Group Holdings
RILY
$284M
| $534K | ﹤0.01% |
179,960
+78,847
| +78% | +$242K |
|
1319
Allegion
ALLE
$13.4B
| $533K | ﹤0.01% |
3,696
+917
| +33% | +$125K |
|
1320
Ball Corp
BALL
$16.8B
| $531K | ﹤0.01% |
9,474
+8,163
| +623% | +$426K |
|
1321
Avis
CAR
$4.89B
| $527K | ﹤0.01% |
3,119
-2,643
| -46% | -$285K |
|
1322
Global Industrial
GIC
$1.51B
| $527K | ﹤0.01% |
19,493
-5,164
| -21% | -$130K |
|
1323
Teradata
TDC
$2.65B
| $524K | ﹤0.01% |
23,486
-484
| -2% | -$10.5K |
|
1324
Cabaletta Bio
CABA
$548M
| $524K | ﹤0.01% |
344,540
+1,129
| +0.3% | +$1.76K |
|
1325
Chord Energy
CHRD
$7.93B
| $522K | ﹤0.01% |
5,392
-396
| -7% | -$37.7K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.